Ligand Pharmaceuticals Incorporated - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LGND Nasdaq 2836 www.ligand.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ligand Pharmaceuticals Incorporated

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates - Nov 10th, 2025 2:10 pm
LGND: Target Up On Improved Growth Outlook - Nov 10th, 2025 8:05 am
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer - Nov 10th, 2025 3:31 am
Ligand Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Nov 9th, 2025 7:18 am
November 2025's Top Stocks Priced Below Estimated Value - Nov 7th, 2025 10:38 am
Ligand (LGND) Q3 2025 Earnings Call Transcript - Nov 6th, 2025 8:46 am
Ligand: Q3 Earnings Snapshot - Nov 6th, 2025 5:14 am
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance - Nov 6th, 2025 5:00 am
How Investors Are Reacting To Ligand Pharmaceuticals (LGND) Management's Engagement Surge and Analyst Optimism - Nov 3rd, 2025 3:07 pm
Orchestra BioMed to Host Business Update Call on November 12, 2025 - Nov 3rd, 2025 6:00 am
Ligand to Participate in November Investor Conferences - Oct 30th, 2025 2:01 pm
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 - Oct 23rd, 2025 5:00 am
Ligand to Host Investor Day on December 9, 2025 - Oct 16th, 2025 5:00 am
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients - Oct 9th, 2025 5:00 am
3 Stocks That May Be Priced Below Intrinsic Value By Up To 44.4% - Oct 8th, 2025 11:38 am
3 Stocks That May Be Trading Below Fair Value Estimates - Sep 9th, 2025 11:44 am
A Fresh Look at Ligand Pharmaceuticals (LGND) Valuation Following $400 Million Convertible Note Offering and Capital Structure Shift - Aug 22nd, 2025 4:15 am
Ligand to Participate in September Investor Conferences - Aug 19th, 2025 2:00 pm
Ligand Announces Closing of Convertible Senior Notes Offering - Aug 14th, 2025 2:00 pm
3 Stocks Estimated To Be Trading At Up To 48.7% Below Intrinsic Value - Aug 12th, 2025 11:37 am